RhumbLine Advisers
DFTX

RhumbLine Advisers’s Definium Therapeutics DFTX Stock Holding History

RhumbLine Advisers’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.44M Buy
158,096
+38,124
+32% +$942K 0.01% 1259
2026
Q1 		$2.27M Buy
119,972
+9,225
+8% +$157K ﹤0.01% 1779
2025
Q4 		$1.48M Sell
110,747
-1,371
-1% -$17K ﹤0.01% 2034
2025
Q3 		$1.32M Sell
112,118
-3,178
-3% -$29.6K ﹤0.01% 2103
2025
Q2 		$748K Buy
115,296
+6,839
+6% +$45K ﹤0.01% 2402
2025
Q1 		$634K Buy
108,457
+7,762
+8% +$55.6K ﹤0.01% 2415
2024
Q4 		$701K Buy
100,695
+4,868
+5% +$33.5K ﹤0.01% 2454
2024
Q3 		$545K Buy
95,827
+1,711
+2% +$11.9K ﹤0.01% 2645
2024
Q2 		$679K Buy
+94,116
New +$823K ﹤0.01% 2460
2022
Q2 		– Sell
-20,112
Closed -$335K – 3185
2022
Q1 		$335K Sell
20,112
-551
-3% -$9.56K ﹤0.01% 2602
2021
Q4 		$428K Buy
20,663
+183
+0.9% +$5.84K ﹤0.01% 2574
2021
Q3 		$716K Buy
20,480
+992
+5% +$42.9K ﹤0.01% 2383
2021
Q2 		$1.01M Buy
+19,488
New +$1.02M ﹤0.01% 2243

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

RhumbLine Advisers's DFTX Position: Q2 2026 in Review

RhumbLine Advisers increased its Definium Therapeutics (DFTX) stake by 32% in Q2 2026, buying an estimated $942K and bringing the position to 158,096 shares worth $7.44M. The position accounts for 0.01% of the portfolio, ranked #1259.

RhumbLine Advisers first reported a position in DFTX in Q2 2021 and has held it in 13 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • RhumbLine Advisers held 158,096 shares of Definium Therapeutics worth $7.44M as of Q2 2026.
  • RhumbLine Advisers bought 38,124 Definium Therapeutics shares in Q2 2026, an estimated $942K.
  • Definium Therapeutics made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1259 holding.
  • RhumbLine Advisers first reported a position in Definium Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.